Management quickly explained why the 1st US clinical trial...

Management quickly explained why the 1st US clinical trial stuffed up and the substantial share holder didn't sell, this issue was quickly resolved and the 2nd US clinical trial was a success, it's not our fault that the market didn't know how to interpret the result so it was sold down back to 7c on low volumes. The pps will recovered to back to where it should have been after the 2nd US clinical trial, mid 30s to low 40s.....Sanofi who has a MC that is 4x bigger than Philips is interested in ResAppDx.....